Subscribe to RSS
DOI: 10.1055/s-0029-1244112
© Georg Thieme Verlag KG Stuttgart · New York
Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinien 2009[*]
Diagnosis and Treatment of Pulmonary Hypertension: European Guidelines 2009Publication History
Publication Date:
18 May 2010 (online)
![](https://www.thieme-connect.de/media/pneumologie/201007/lookinside/thumbnails/10.1055-s-0029-1244112-1.jpg)
Vorbemerkung
Die ersten deutschen Leitlinien zur pulmonalen Hypertonie sind 2006 erschienen [1] [2]. Diese lehnten sich an die 2004 veröffentlichten Leitlinien der European Society of Cardiology an [3]. Im August 2009 wurden die aktualisierten Europäischen Leitlinien zur pulmonalen Hypertonie publiziert, die erstmalig gemeinsam von der European Society of Cardiology (ESC) und der European Respiratory Society (ERS) erstellt wurden [4] [5]. Die Deutsche Gesellschaft für Kardiologie (DGK) übernimmt seit einigen Jahren die von der ESC herausgegebenen Leitlinien. Eigene Leitlinien werden von der DGK nicht mehr erstellt. Auch die Arbeitsgruppen Pulmonale Hypertonie der Deutschen Gesellschaften für Pneumologie (DGP) und Pädiatrische Kardiologie (DGPK) haben vereinbart, in Zukunft keine neuen deutschen Leitlinien zur pulmonalen Hypertonie zu erstellen. Gemeinsam haben die jeweiligen Arbeitsgruppen Pulmonale Hypertonie die Aufgabe übernommen, die ESC/ERS-Leitlinien in Kurzform zusammenzufassen und hinsichtlich Länder-spezifischer Aspekte zu kommentieren. Im nachfolgenden Text werden die ESC/ERS-Leitlinien in Kurzform zusammengefasst. Für Deutschland bestehende Besonderheiten, die an einigen Stellen hinzugefügt wurden, sind im Text jeweils kursiv hervorgehoben. Es handelt sich bei diesem Text ausdrücklich nicht um eine Leitlinie, sondern um eine übersetzte Kurzfassung der europäischen Leitlinien.
1 Dieser Beitrag wurde in den Zeitschriften Deutsche Medizinische Wochenschrift (DOI 10.1055/s-0030-1248657), Der Kardiologe (DOI 10.1007/s12181-010-0269-z) und Pneumologie (DOI 10.1055/s-0029-1244112) in gleicher Form publiziert.
Literatur
- 1 Olschewski H, Hoeper M M, Borst M M. et al . Diagnosis and therapy of chronic pulmonary hypertension. Pneumologie. 2006; 60 749-771
- 2 Olschewski H, Hoeper M M, Borst M M. et al . Diagnostik und Therapie der chronischen pulmonalen Hypertonie. Clin Res Cardiol. 2007; 96 301-330
- 3 Galie N, Torbicki A, Barst R. et al . Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004; 25 2243-2278
- 4 Galie N, Hoeper M M, Humbert M. et al . Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J. 2009; 34 1219-1263
- 5 Galie N, Hoeper M M, Humbert M. et al . Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30 2493-2537
- 6 Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009; 34 888-894
- 7 Badesch D B, Champion H C, Sanchez M A. et al . Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54 55-66
- 8 Rich S, Dantzker D R, Ayres S M. et al . Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987; 107 216-223
- 9 Tongers J, Schwerdtfeger B, Klein G. et al . Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J. 2007; 153 127-132
- 10 Hoeper M M, Pletz M W, Golpon H, Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2007; 29 944-950
- 11 Fisher M R, Forfia P R, Chamera E. et al . Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179 615-621
- 12 Arcasoy S M, Christie J D, Ferrari V A. et al . Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003; 167 735-740
- 13 Fisher M R, Criner G J, Fishman A P. et al . Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J. 2007; 30 914-921
- 14 Tunariu N, Gibbs S J, Win Z. et al . Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007; 48 680-684
- 15 Resten A, Maitre S, Humbert M. et al . Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol. 2004; 183 65-70
- 16 Reichelt A, Hoeper M M, Galanski M, Keberle M. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. Eur J Radiol. 2009; 71 49-54
- 17 Hoeper M M, Lee S H, Voswinckel R. et al . Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006; 48 2546-2552
- 18 Jing Z C, Jiang X, Han Z Y. et al . Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J. 2009; 33 1354-1360
- 19 Sitbon O, Humbert M, Jais X. et al . Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111 3105-3111
- 20 Galie N, Manes A, Negro L. et al . A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009; 30 394-403
- 21 Mereles D, Ehlken N, Kreuscher S. et al . Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006; 114 1482-1489
- 22 de Man F S, Handoko M L, Groepenhoff H. et al . Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2009; 34 669-675
- 23 Dupuis J, Hoeper M M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008; 31 407-414
- 24 Wilkins M R, Wharton J, Grimminger F, Ghofrani H A. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J. 2008; 32 198-209
- 25 Olschewski H, Gomberg-Maitland M. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008; 31 801-901
- 26 Barst R J, Rubin L J, Long W A. et al . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996; 334 296-302
- 27 Barst R J, Langleben D, Frost A. et al . Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 169 441-447
- 28 Barst R J, Langleben D, Badesch D. et al . Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006; 47 2049-2056
- 29 Galie N, Brundage B H, Ghofrani H A. et al . Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119 2894-2903
- 30 Galie N, Olschewski H, Oudiz R J. et al . Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117 3010-3019
- 31 Galie N, Rubin L, Hoeper M. et al . Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371 2093-2100
- 32 Galie N, Beghetti M, Gatzoulis M A. et al . Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114 48-54
- 33 Galie N, Ghofrani H A, Torbicki A. et al . Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med. 2005; 353 2148-2157
- 34 Rubin L J, Badesch D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346 896-903
- 35 Channick R N, Simonneau G, Sitbon O. et al . Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358 1119-1123
- 36 Simonneau G, Rubin L J, Galie N. et al . Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008; 149 521-530
- 37 Simonneau G, Barst R J, Galie N. et al . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165 800-804
- 38 Olschewski H, Simonneau G, Galie N. et al . Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347 322-329
- 39 Oudiz R J, Galie N, Olschewski H. et al . Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54 1971-1981
- 40 Hoeper M M, Gall H, Seyfarth H J. et al . Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J. 2009; 34 132-137
- 41 McLaughlin V V, Oudiz R J, Frost A. et al . Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006; 174 1257-1263
- 42 Hoeper M M, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005; 26 858-863
- 43 Mukerjee D, St George D, Coleiro B. et al . Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003; 62 1088-1093
- 44 Bull T M, Fagan K A, Badesch D B. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am. 2005; 31 451-464, vi
- 45 Hoeper M M, Seyfarth H J, Hoeffken G. et al . Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007; 30 1096-1102
- 46 Reichenberger F, Voswinckel R, Steveling E. et al . Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006; 28 563-567
- 47 Grannas G, Neipp M, Hoeper M M. et al . Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases. Transplantation. 2008; 85 524-531
- 48 Sitbon O, Lascoux-Combe C, Delfraissy J F. et al . Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008; 177 108-113
- 49 Grigioni F, Potena L, Galie N. et al . Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant. 2006; 25 1241-1246
- 50 Califf R M, Adams K F, McKenna W J. et al . A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997; 134 44-54
- 51 Packer M, McMurray J, Massie B M. et al . Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail. 2005; 11 12-20
- 52 Alaeddini J, Uber P A, Park M H. et al . Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol. 2004; 94 1475-1477
- 53 Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi M D. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007; 50 2136-2144
- 54 Lewis G D, Shah R, Shahzad K. et al . Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007; 116 1555-1562
- 55 Lewis G D, Lachmann J, Camuso J. et al . Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007; 115 59-66
- 56 Behr J, Ryu J H. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008; 31 1357-1367
- 57 Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008; 32 1371-1385
- 58 Stolz D, Rasch H, Linka A. et al . A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008; 32 619-628
- 59 Chaouat A, Bugnet A S, Kadaoui N. et al . Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172 189-194
- 60 Thabut G, Dauriat G, Stern J B. et al . Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005; 127 1531-1536
- 61 Hoeper M M, Mayer E, Simonneau G, Rubin L J. Chronic Thromboembolic Pulmonary Hypertension. Circulation. 2006; 113 2011-2020
- 62 Jais X, D'Armini A M, Jansa P. et al . Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial. J Am Coll Cardiol. 2008; 52 2127-2134
- 63 Hughes R J, Jais X, Bonderman D. et al . The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J. 2006; 28 138-143
- 64 Hughes R, George P, Parameshwar J. et al . Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax. 2005; 60 707
- 65 Bonderman D, Nowotny R, Skoro-Sajer N. et al . Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005; 128 2599-2603
- 66 Hoeper M M, Kramm T, Wilkens H. et al . Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005; 128 2363-2367
- 67 Ghofrani H A, Schermuly R T, Rose F. et al . Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2003; 167 1139-1141
- 68 Reichenberger F, Voswinckel R, Enke B. et al . Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2007; 30 922-927
- 69 Bresser P, Fedullo P F, Auger W R. et al . Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004; 23 595-600
1 Dieser Beitrag wurde in den Zeitschriften Deutsche Medizinische Wochenschrift (DOI 10.1055/s-0030-1248657), Der Kardiologe (DOI 10.1007/s12181-010-0269-z) und Pneumologie (DOI 10.1055/s-0029-1244112) in gleicher Form publiziert.
2 Die Autoren sind die Sprecher der Arbeitsgruppen Pulmonale Hypertonie der Deutschen Gesellschaft für Pneumologie (M.M.H, H.A.G.), der Deutschen Gesellschaft für Kardiologie (E.G., S.R.) und der Deutschen Gesellschaft für Pädiatrische Kardiologie (M.G., D.S.).
Prof. Dr. med. Marius M. Hoeper
Abteilung Pneumologie
Medizinische Hochschule Hannover
30625 Hannover
Email: hoeper.marius@mh-hannover.de